Impaired Insulin Sensitivity, Insulin Secretion, and Glucose Effectiveness Predict Future Development of Impaired Glucose Tolerance and Type 2 Diabetes in Pre-Diabetic African Americans
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—We examined the determinants of impaired glucose tolerance (IGT) and type 2 diabetes in first-degree relatives of African-American type 2 diabetic patients over 5–8 years (median 6). RESEARCH DESIGN AND METHODS—A total of 81 healthy subjects (age 41.5 ± 4.8 years; BMI 31.3 ± 3.6 kg/m2) participated in the study. Each subject underwent an oral glucose tolerance test (OGTT) and a frequently sampled intravenous glucose tolerance test at baseline. Insulin sensitivity index (Si) and glucose effectiveness index (Sg) were determined by the minimal model method. Homeostasis model assessment (HOMA) was used to estimate insulin resistance (HOMA-IR) and β-cell function (HOMA-%B). A total of 18 subjects progressed to either IGT or type 2 diabetes (progressors), whereas 19 subjects maintained normal glucose tolerance (nonprogressors). RESULTS—Comparing the progressors and nonprogressors, mean fasting serum glucose levels (95 ± 8 vs. 80 ± 14 mg/dl, P < 0.01) and 2-h serum glucose levels (149 ± 27 vs. 100 ± 60 mg/dl, P < 0.01) as well as 2-h serum insulin levels (117 ± 81 vs. 72 ± 87 μU/ml, P < 0.01) during OGTT were higher at baseline. Mean acute first-phase insulin secretion (205 ± 217 vs. 305 ± 230 μU/ml), HOMA-%B (148 ± 60 vs. 346 ± 372, P < 01), Si (1.61 ± 1.13 vs. 2.48 ± 1.25 × 10−4 · min−1 [μU/ml]−1), and Sg (1.48 ± 0.61 vs. 2.30 ± 0.97 × 10−2 · min−1) were lower in the progressors than in the nonprogressors at baseline. Mean HOMA-IR (3.31 ± 1.64 vs. 2.36 ± 1.64) was significantly greater in the progressors than the nonprogressors. At the time of diagnosis of glucose intolerance (IGT + diabetes), HOMA-%B (101 ± 48 vs. 148 ± 60, P < 0.001) and HOMA-IR (5.44 ± 2.55 vs. 3.31 ± 1.64, P < 0.003) deteriorated in the progressors versus baseline. CONCLUSIONS—We conclude that nondiabetic, first-degree relatives of African-American type 2 diabetic patients who progressed to IGT and type 2 diabetes manifest triple defects (decreased insulin secretion, insulin action, and glucose effectiveness) that antecede the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“These findings were consistent with those found in other populations (20,21).”
ResultHarris, M. I., Flegal, K. M., Cowie, C. C., Eberhardt, M. S., Goldstein, D. E., Little, R. R., Wiedmeyer, H.-M., & Byrd-Holt, D. D. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.518 · Cited by 2,703
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
Weyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940
Martin, B. C., Warram, J. H., Krolewski, A. S., Soeldner, J. S., Kahn, C. R., Martin, B. C., & Bergman, R. N. (1992) · The Lancet · doi:10.1016/0140-6736(92)92814-v · Cited by 1,158
Toward Physiological Understanding of Glucose Tolerance: Minimal-Model Approach
Bergman, R. N. (1989) · Diabetes · doi:10.2337/diab.38.12.1512 · Cited by 1,001
Global Estimates for Prevalence of Diabetes Mellitus and Impaired Glucose Tolerance in Adults
King, H., Rewers, M., & Who Ad Hoc Diabetes Reporting Group (1993) · Diabetes Care · doi:10.2337/diacare.16.1.157 · Cited by 886
Lean body mass estimation by bioelectrical impedance analysis: a four-site cross-validation study
Segal, K., Van Loan, M., Fitzgerald, P., Hodgdon, A., & Van Itallie, T. (1988) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/47.1.7 · Cited by 881
Early Metabolic Defects in Persons at Increased Risk for Non-Insulin-Dependent Diabetes Mellitus
Eriksson, J., Franssila-Kallunki, A., Ekstrand, A., Saloranta, C., Widén, E., Schalin, C., & Groop, L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908103210601 · Cited by 807
Bergman, R. N., Prager, R., Volund, A., & Olefsky, J. M. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112886 · Cited by 772
Haffner, S. M., Ralph, D., Saad, M. F., Rewers, M., Mykkänen, L., Selby, J., Howard, G., Savage, P. J., Hamman, R. F., Wegenknecht, L. E., et al. (1996) · Diabetes · doi:10.2337/diab.45.6.742 · Cited by 536
DeFronzo, R. A., Ferrannini, E., & Simonson, D. C. (1989) · Metabolism · doi:10.1016/0026-0495(89)90129-7 · Cited by 515
Kahn, S. E., Prigeon, R. L., McCulloch, D. K., Boyko, E. J., Bergman, R. N., Schwartz, M. W., Neifing, J. L., Ward, W. K., Beard, J. C., Palmer, J. P., et al. (1993) · Diabetes · doi:10.2337/diabetes.42.11.1663 · Cited by 328
Role of Glucose Effectiveness in the Determination of Glucose Tolerance
Best, J. D., Kahn, S. E., Ader, M., Watanabe, R. M., Ni, T. C., & Bergman, R. N. (1996) · Diabetes Care · doi:10.2337/diacare.19.9.1018 · Cited by 290
Saad, M., Pettitt, D., Mott, D., Knowler, W., Nelson, R., & Bennett, P. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92804-3 · Cited by 265
Increased Insulin Concentrations in Nondiabetic Offspring of Diabetic Parents
Haffner, S. M., Stern, M. P., Hazuda, H. P., Mitchell, B. D., & Patterson, J. K. (1988) · New England Journal of Medicine · doi:10.1056/nejm198811173192001 · Cited by 238
Vaag, A., Henriksen, J. E., Madsbad, S., Holm, N., & Beck-Nielsen, H. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117715 · Cited by 206
Cited by
Grassi, D., Desideri, G., Necozione, S., Lippi, C., Casale, R., Properzi, G., Blumberg, J. B., & Ferri, C. (2008) · The Journal of Nutrition · doi:10.1093/jn/138.9.1671 · Cited by 481
“Conditions of insulin resistance such as impaired glucose tolerance (IGT) or ‘‘prediabetes’’ (13) are characterized by high risk of CVD (14) and diabetes (15), decreased endothelial NO bioavailability with impaired endothelium-dependent vasorelaxation (16), and increased oxidative stress (17).”
BackgroundPathogenesis of Type 2 Diabetes Mellitus
Leahy, J. L. (2005) · Archives of Medical Research · doi:10.1016/j.arcmed.2005.01.003 · Cited by 469
Song, Y., Manson, J. E., Tinker, L., Howard, B. V., Kuller, L. H., Nathan, L., Rifai, N., & Liu, S. (2007) · Diabetes Care · doi:10.2337/dc07-0358 · Cited by 360
Maggio, C. A., & Pi-Sunyer, F. X. (2003) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(03)00071-9 · Cited by 351
Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia
Richter, B., Hemmingsen, B., Metzendorf, M.-I., & Takwoingi, Y. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012661.pub2 · Cited by 283
Metadata
- Authors
- Osei, K., Rhinesmith, S., Gaillard, T., & Schuster, D.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2004-06-01
- Volume
- 27
- Issue
- 6
- Pages
- 1439-1446
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2024140290
- Cited by
- 117
- References
- 19
- FWCI
- 3.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.